Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase II Clinical Study of the Efficacy and Safety of QA108 Granules in the Treatment of Intermediate Age-Related Macular Degeneration

NCT05562219 is registered in ClinicalTrials.gov with Smilebiotek Zhuhai Limited as lead sponsor.

NCT NCT05562219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05562219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase II Clinical Study of the Efficacy and Safety of QA108 Granules in the Treatment of Intermediate Age-Related Macular Degeneration
Lead sponsor
Smilebiotek Zhuhai Limited
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2022
Completion date
June 24, 2024
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intermediate age-related macular degeneration